<VariationArchive RecordType="classified" VariationID="1683226" VariationName="NC_000014.8:g.(?_88399357)_(88417093_88429727)del" VariationType="Deletion" Accession="VCV001683226" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2022-05-16" MostRecentSubmission="2022-05-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1675125" VariationID="1683226">
      <GeneList>
        <Gene Symbol="GALC" FullName="galactosylceramidase" GeneID="2581" HGNC_ID="HGNC:4115" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>14q31.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87933014" stop="87993667" display_start="87933014" display_stop="87993667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88399357" stop="88460008" display_start="88399357" display_stop="88460008" Strand="-" />
          </Location>
          <OMIM>606890</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000014.8:g.(?_88399357)_(88417093_88429727)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>14q31.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" innerStart="88399357" innerStop="88417093" outerStop="88429727" display_start="88399357" display_stop="88429727" variantLength="30371" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.(?_88399357)_(88417093_88429727)del" Assembly="GRCh37">
            <Expression>NC_000014.8:g.(?_88399357)_(88417093_88429727)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000014.8:g.(?_88399357)_(88417093_88429727)del AND Galactosylceramide beta-galactosidase deficiency" Accession="RCV002238556" Version="1">
        <ClassifiedConditionList TraitSetID="1051">
          <ClassifiedCondition DB="MedGen" ID="C0023521">Galactosylceramide beta-galactosidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-26" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-05-16" MostRecentSubmission="2022-05-16">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20886637</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22073273</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26795590</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7581365</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8634707</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8687180</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8940268</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9266397</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1051" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Globoid cell leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Galactosylceramide beta-galactosidase deficiency</ElementValue>
                <XRef ID="Krabbe+leukodystrophy/4044" DB="Genetic Alliance" />
                <XRef ID="192782005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Krabbe leukodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, Globoid Cell</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GCL</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GLD</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</Attribute>
                <XRef ID="NBK1238" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6844" />
                <XRef ID="6844" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301416</ID>
                <ID Source="BookShelf">NBK1238</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, elevated psychosine, Krabbe Disease (infantile form), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Krabbe disease: galactocerebrosidase deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, mildly elevated psychosine, Krabbe Disease (late-onset form), 2022</CitationText>
              </Citation>
              <XRef ID="487" DB="Orphanet" />
              <XRef ID="C0023521" DB="MedGen" />
              <XRef ID="MONDO:0009499" DB="MONDO" />
              <XRef Type="MIM" ID="245200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4908008" SubmissionDate="2022-05-12" DateLastUpdated="2022-05-16" DateCreated="2022-05-16">
        <ClinVarSubmissionID localKey="NC_000014.8:g.(?_88399357)_(88417093_88429727)del|MedGen:C0023521" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002511404" DateUpdated="2022-05-16" DateCreated="2022-05-16" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20886637</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9266397</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7581365</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26795590</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8940268</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8687180</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22073273</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8634707</ID>
          </Citation>
          <Comment>Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 11-17, which includes the last exon in the in the GALC gene. A presumed nomenclature of c.(1161+1_1162-1)_(*1719_?)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is not expected to cause nonsense mediated decay (NMD), but is predicted to cause a large truncation of the encoded protein (removing amino acids 388-685). A large deletion variant (size 31,666 bp; position chr14: 88391506-88423172) was found at a frequency of 0.00037 in 21694 control chromosomes (i.e. 8 heterozygotes) in the gnomAD database, structural variants dataset. This particular large deletion variant is also known as the common Caucasian 30-kb GALC gene deletion (aka. del30kb or c.1161+6532_polyA+9kbdel), and is reported in numerous homozygous- and compound heterozygous patients affected with Krabbe Disease (see e.g. Rafi_1995, Luzi_1995, Luzi_1996, De Gasperi_1996, Kleijer_1997, Tappino_2010, Orsini_2016). In addition, this variant has been also reported in heterozygous form in association with an increased risk for primary open-angle glaucoma, although the clinical significance of this finding is unclear (Liu_2011). A publication reported experimental evidence evaluating an impact on protein function, and demonstrated no measureable GALC activity in cells transfected with a cDNA where all coding sequences beyond exon 10 were removed (Rafi_1995). At least one clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000014.8:g.(?_88399357)_(88417093_88429727)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023521" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11463985</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4908008" TraitType="Disease" MappingType="XRef" MappingValue="C0023521" MappingRef="MedGen">
        <MedGen CUI="C0023521" Name="Galactosylceramide beta-galactosidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

